Herein, we demonstrate that NXP800, a heat shock factor 1 pathway inhibitor in clinical development, activates the unfolded protein response and inhibits AR- and E2F-mediated transcription as well as the growth of treatment-resistant prostate cancer models. The gene discussed is AR; the disease is Familial prostate cancer.